Atlas›Domain XVI · Historical, discredited & harmful›Guide 040
Guide XVI-040

Nerve tonics, sedative powders and serum injections

1870
A 23 · L 69 · M 820 interventions in the Trinity explorer
Client cardCompare
[source: …] where a claim comes from[uncertain] not confirmed in a primary source[synthesis] the writer's reconstruction

1. Introduction

Version followed: the historical record of branded nerve tonics, "nerve" sedative powders and "neurasthenic" serum or extract injections (c. 1870-1960) as the British Medical Association's analyses (Secret Remedies, 1909; More Secret Remedies, 1912), the Science Museum Group, the Oskar Diethelm Library (Weill Cornell) and the US Food and Drug Administration (FDA) document it, with present-day harms from peer-reviewed and regulator sources. The psychotherapist's own work in sections 4-5 is [synthesis] built on these sources. This guide does not describe how any product was made, dosed or used. Patent medicines more broadly are covered in guide 046, and radioactive and electrical products in guide 045.

Nerve tonics are a family of commercial and quasi-medical products, not a therapy. It is listed for the history of ideas and for safety: several products contained addictive or toxic substances, were given to infants, or delayed proper care, and none is recommended.

The proponents' idea of change. The products rested on the late-19th-century theory that the nerves held a limited store of "nerve force" that modern life used up. The New York neurologist George M. Beard set out "neurasthenia" (nervous exhaustion) in 1880 and in American Nervousness (1881), attributing nervousness to a lack of "nerve-force" and overexposure to "modern civilization" [source: Oskar Diethelm Library exhibit]. The Science Museum notes that the American asylum doctor Edwin Holmes Van Deusen coined the term, that Beard popularised it, and that it became a catch-all diagnosis, never caught on in Britain and later dropped out of medical use [source: Science Museum, From nerves to neuroses]. Sellers claimed that a tonic would "tone" or rebuild the nerves, that a powder would calm them, and that an injected serum or animal extract would restore vigour. The Science Museum explains that the word "tonic" came from the outdated idea that organs needed "tone" [source: Science Museum]. In 1889 the physiologist Charles-Édouard Brown-Séquard, then 72, told a Paris scientific meeting that injections of animal testicular extract had rejuvenated him; the historian Chandak Sengoopta records that he drew "more than his fair share of derision", while the wider idea of organ extracts later proved fruitful in endocrinology [source: History Today, Secrets of Eternal Youth]. In outline, the proponents promised that change came from putting back a missing substance or force, with no psychological work needed.

How it was discredited. The BMA had the products chemically analysed and printed the advertised claims beside the findings. Its 1912 preface held that "the more extravagant the claims made", the more surely the composition showed little or no value, or even harm [source: BMA, More Secret Remedies, 1912, Project Gutenberg edition]. The analyses repeatedly found cheap, ordinary ingredients sold at many times their cost, some mislabelled (for example, products sold as opium-free that contained morphine) [source: BMA, Secret Remedies, 1909, Project Gutenberg edition]. The Science Museum records that many tonics contained strychnine, morphine, lithium salts or cocaine ("powerful, poorly understood, and often addictive") and that many were banned in the early 1900s once laws required ingredient labelling [source: Science Museum]. In the United States the 1906 Food and Drugs Act targeted misbranding; the 1912 Sherley Amendment barred false therapeutic claims made to defraud; the 1938 Federal Food, Drug, and Cosmetic Act required safety to be shown before marketing; and the 1962 amendments required proof of effectiveness [source: FDA, Milestones in US Food and Drug Law]. UK statutory control of ingredient disclosure (often dated to the Pharmacy and Medicines Act 1941) [uncertain: not verified].

What survives today. "Nerve", "calm", "nootropic" and "adaptogen" products are still sold online, in convenience stores and in vape shops. In 2023-2025 the FDA warned the public not to buy or use any tianeptine product (sold as "nootropics", "research chemicals" or dietary supplements with claims to treat anxiety and depression), citing seizures, loss of consciousness and death [source: FDA tianeptine warning]. Bromide toxicity (bromism), once common among users of bromide "nerve" remedies, still occurs through unregulated online products and imported remedies [source: Packer, Psychiatric Times, 2025]. Clients meet these products through advertising, social media, wellness retail, family habit and online or chatbot health advice.

2. Framework

The framework has two strands: the historical phases of the trade, in outline, for recognition; and the phases of the psychotherapist's own work. Session numbers are set by clinical need [synthesis].

Historical phases (outline).

  • c. 1870-1900, the "nerves" market. Neurasthenia, the rest cure and electrotherapy flourish among wealthier patients; mass-market branded tonics, "nerve" pills and headache or "nerve" powders are sold to everyone else, often with testimonials and guarantees [source: Science Museum; Oskar Diethelm Library; BMA 1909].
  • 1889 onwards, organ extracts and "serums". Brown-Séquard's report of rejuvenating injections is followed by commercial "neurasthenic serums"; the Science Museum holds an example ("Azoule neurasthenic serum") that contained strychnine [source: History Today; Science Museum].
  • 1906-1938, exposure and regulation. Muckraking analyses (the BMA volumes in Britain) and US federal law target misbranding, false claims and, after the 1937 Elixir Sulfanilamide deaths (107 people), safety before sale [source: FDA Milestones; BMA 1909, 1912].
  • c. 1920-1960, sedative and tonic products persist. Products such as "Coneuro" were marketed both as a "nerve sedative" and as a nerve tonic between 1920 and 1960; Huxley's "Ner-Vigor" (sold 1892-1943, containing a small amount of strychnine) was marketed for depression and neurasthenia and was probably taken by First World War veterans with "shell-shock" [source: Science Museum; Science Museum Group collection]. Bromide remedies decline as regulation tightens; one long-running brand removed bromide only in 1975 [source: Packer 2025].
  • 1994 to now, supplements and "nootropics". In the US, the 1994 Dietary Supplement Health and Education Act classes supplements as food [source: FDA Milestones]; unapproved "mood", "focus" and "calm" products reappear online and in shops [source: FDA tianeptine warning].

Phases of the psychotherapist's work [synthesis].

  1. Recognition and assessment. Goal: learn what the client takes or is drawn to, and whether symptoms could have a toxic or medical cause. Move on when you have a product history and know whether a medical review is needed.
  2. Safety and medical routing. Goal: get any possible toxicity, dependence, interaction or child-safety concern to the right medical, poison-control or safeguarding service. Move on when urgent risks are handed to the right service and the client knows how to get help.
  3. Exploration and psychoeducation. Goal: understand the meaning of "nerves" for this client, share the history of the claims, and build skills in judging health claims. Move on when the client can weigh claims for themselves.
  4. Supported care and repair. Goal: offer evidence-based help for the underlying distress (anxiety, low mood, insomnia, fatigue), work through shame, anger or grief where a product or a relative's use caused harm, and rebuild trust in care.
  5. Advocacy and follow-up. Goal: adverse-event reporting, professional duties if a colleague sells or recommends such products, family-history work and relapse planning.

3. Guiding principles

  • Never provide, recommend, supervise or refer to a nerve tonic, sedative powder, "serum" or look-alike product. Practical meaning: your role is psychological care, recognition and routing, never product advice [synthesis].
  • Never advise starting, stopping or changing any medicine or supplement. Practical meaning: questions about stopping, reducing or combining go to the prescriber, pharmacist or poison-control service [synthesis].
  • Think medically first when the picture is new or odd. Practical meaning: new confusion, hallucinations, paranoia, memory loss or a skin eruption in someone using remedies calls for medical review, because bromism can look like a primary psychiatric illness and is often missed [source: Packer 2025; Clinical Toxicology case report].
  • Curiosity, not ridicule. Practical meaning: people bought tonics because they were exhausted, anxious and poorly served; ask what the product promised them [synthesis].
  • Claims are weighed against evidence, as the BMA did. Practical meaning: help clients compare what is promised with what is known, rather than giving a verdict [source: BMA 1912 preface; synthesis].
  • The distress is real even when the remedy was not. Practical meaning: take the underlying "nerves" (anxiety, low mood, fatigue, insomnia) seriously and offer supported care [synthesis].
  • Historical diagnoses are historical. Practical meaning: "neurasthenia" was a catch-all that left medical use; do not adopt it as a present diagnosis, but respect it as a family or cultural idiom [source: Science Museum; Oskar Diethelm Library].
  • Children and dependent adults first. Practical meaning: any unapproved sedative or "soothing" product given to an infant, child or dependent adult raises a safeguarding question; the FDA records that one unlabelled soothing syrup containing morphine "killed many infants" [source: FDA Milestones].
  • Respect autonomy within safety limits. Practical meaning: an adult may keep using a legal product; your job is informed choice, medical routing and keeping the alliance [synthesis].
  • No glamorising the past. Practical meaning: vintage bottles and "Victorian remedies" can look charming; keep harm, cost and exploitation in view [synthesis].
  • Report what should be reported. Practical meaning: adverse reactions can be reported to the regulator (FDA MedWatch in the US) [source: FDA tianeptine warning]; colleague concerns follow professional routes [synthesis].
  • Avoid commercial entanglement. Practical meaning: selling or promoting products to clients creates a conflicting relationship; see APA Ethics Code Standard 3.05 (Multiple Relationships) [source: APA Ethics Code; application synthesis].

4. Intervention inventory

The interventions below are the psychotherapist's own work; steps not drawn from a cited source are marked [synthesis]. None of them involves giving, recommending or adjusting any product or medicine.

4.1 Historical literacy for yourself and your team

  • Purpose / when: Before working with clients who use "nerve", "calm" or "brain" products, or who bring family stories of tonics and "nerves". Gives you the context to recognise the pattern without mocking it.
  • Steps: (1) Learn the core ideas in outline: "nerve force", neurasthenia, tonics, "nerve" powders and "serums" [source: Oskar Diethelm Library; Science Museum]. (2) Learn the discrediting record: the BMA's claim-versus-analysis method and the US regulatory steps of 1906, 1912, 1938 and 1962 [source: BMA 1909, 1912; FDA Milestones]. (3) Learn the main documented harms: hidden addictive ingredients, bromide toxicity, deaths of infants given unlabelled soothing syrups [source: Science Museum; Packer 2025; FDA Milestones]. (4) Share a one-page summary in team meetings [synthesis].
  • Example language (illustrative): "Many of the 'nerve' products sold a century ago promised to restore lost nerve energy. The British Medical Association analysed them and found mostly cheap ingredients, some of them dangerous."
  • Watch for: Talking about the past with contempt for the people who bought these products; overstating what is known (for example, exact admission rates for bromism, which the sources call hard to document). Working when: you can explain the history in neutral terms and connect it to present-day products.

4.2 Asking about remedies, supplements and "nerve" products at intake

  • Purpose / when: At every intake and at review, especially with anxiety, insomnia, fatigue, low mood or "burnout".
  • Steps: (1) Ask a routine, non-judging question about anything the client takes for nerves, sleep, stress, focus or energy, including online, imported, shop-bought, "natural" and family remedies. (2) Ask about where products were bought and what they promised. (3) Record names as the client gives them. (4) Do not comment on safety or dose; note anything to pass on to the client's doctor or pharmacist (see 4.5) [synthesis].
  • Example language (illustrative): "Lots of people take something for their nerves or sleep, whether it's from a doctor, a shop, online or a family recipe. What do you use, if anything?"
  • Watch for: Shame or secrecy (clients expect criticism); products bought from gas stations, vape shops or online "research chemical" sites, which the FDA names as outlets for unapproved tianeptine products [source: FDA tianeptine warning]. Working when: clients disclose freely and you have a clear list to share with medical colleagues (with consent).

4.3 Recognising a possible toxic or medical presentation

  • Purpose / when: When a client who uses remedies shows new or changed confusion, disorientation, hallucinations, paranoia, aggression, memory loss, drowsiness or an acne-like skin eruption.
  • Steps: (1) Keep a toxic or medical cause in mind rather than assuming a primary psychiatric illness; bromism can cause hallucinations, paranoia and confusion without any prior psychiatric history, and is often misdiagnosed [source: Packer 2025]. A French case report describes a woman admitted to a psychiatric department with confusion, hallucinations and memory loss from a non-prescription bromide product, and the authors urge that bromism stay in the differential diagnosis [source: Clinical Toxicology case report]. (2) Do not try to diagnose; describe what you observe. (3) Arrange a prompt medical review and share the product history (with consent, or under your safety policy if urgent) [synthesis].
  • Example language (illustrative): "Some of what you're describing could have a physical cause, including something in a product you've been taking. I'd like you to see a doctor about this soon, and to take the bottle or packet with you."
  • Watch for: Anchoring on a psychological explanation; a client too confused to consent (follow your emergency and capacity procedures). Working when: the medical team has the product history and a medical cause has been ruled in or out.

4.4 Urgent safety response to an acute reaction

  • Purpose / when: When a client, or someone they describe, has a serious reaction after taking a product.
  • Steps: (1) If the person is unconscious or has trouble breathing, call emergency services (911 in the US) [source: FDA tianeptine warning]; in the UK and Ireland call 999 or 112 [synthesis]. (2) For advice in the US, Poison Help is 1-800-222-1222 [source: FDA tianeptine warning]. (3) Keep the product and packaging for the medical team. (4) Follow up and document [synthesis].
  • Example language (illustrative): "This needs medical help right now. I'm going to call for an ambulance and stay with you on the line."
  • Watch for: Delay because the product is "only a supplement"; the FDA reports seizures, loss of consciousness and death with tianeptine products marketed as supplements [source: FDA tianeptine warning]. Working when: the person reaches care quickly and the event is documented.

4.5 Coordinating with the prescriber, GP or pharmacist

  • Purpose / when: Whenever a client takes a product alongside prescribed medicines, wants to stop or change something, or has symptoms that might be product-related.
  • Steps: (1) Get consent to share the product list. (2) Contact the prescriber or encourage the client to book a medication review with a pharmacist. (3) Pass on observations, not advice. (4) Note the outcome [synthesis]. The FDA warns of potentially life-threatening interactions between tianeptine and other medicines [source: FDA tianeptine warning].
  • Example language (illustrative): "I can't advise you on what to take or stop; that's for your doctor or pharmacist. Would it help if I wrote down what you've told me so you can show them?"
  • Watch for: Being drawn into product advice; a client stopping something abruptly on their own (route it to the prescriber at once). Working when: a named medical professional knows what the client takes.

4.6 Exploring what "nerves" means for this client

  • Purpose / when: When a client describes "bad nerves", "burnt-out nerves", "nervous exhaustion" or similar, or is drawn to products that promise to restore them.
  • Steps: (1) Ask for the client's own words and story of the problem. (2) Ask where the idea came from (family, culture, advertising, online). (3) Use the DSM-5-TR Cultural Formulation Interview to explore explanatory models [synthesis]. (4) Translate gently into shared working terms (stress, anxiety, low mood, poor sleep) without dismissing the client's idiom. The ICD-10 retained neurasthenia as a neurotic disorder with culturally variable symptoms, while DSM-IV-TR dropped it [source: Oskar Diethelm Library].
  • Example language (illustrative): "When you say your nerves are worn out, what does that feel like day to day? And what do you think wore them out?"
  • Watch for: Imposing your own model; missing a medical cause of fatigue (route to a doctor). Working when: you and the client share a working description of the problem.

4.7 Psychoeducation on how the claims were tested

  • Purpose / when: With a client drawn to a tonic or "calm" product, or curious about old family remedies.
  • Steps: (1) Describe, in outline, how the BMA set the advertised claims beside chemical analysis and price, and found cheap, ordinary ingredients and sometimes mislabelled ones [source: BMA 1909, 1912]. (2) Describe how US law moved from banning misbranding (1906) to requiring safety (1938) and effectiveness (1962) for drugs, while supplements are regulated as food (1994) [source: FDA Milestones]. (3) Invite the client to apply the same questions to the product they are considering [synthesis].
  • Example language (illustrative): "A century ago doctors simply compared what the label promised with what was in the bottle. We can ask the same questions together about what you've been looking at."
  • Watch for: Lecturing; the client hearing it as an attack on a relative who used such remedies. Working when: the client starts asking their own questions about claims.

4.8 Weighing marketing claims together

  • Purpose / when: When a client brings an advert, website or social-media post for a "nerve", "stress" or "brain" product.
  • Steps: (1) Read the claim together. (2) Look for the features the BMA documented in early-20th-century advertising: sweeping or cure-all claims, testimonials, guarantees with hard conditions, attacks on the medical profession, secrecy about contents, and repeated follow-up letters [source: BMA 1909, 1912]. (3) Look for the present-day equivalents named by the FDA: "nootropic", "research chemical" or supplement labels with claims to treat anxiety or depression [source: FDA tianeptine warning]. (4) Ask what independent evidence would change the client's view. (5) Suggest checking regulator warnings and asking a pharmacist [synthesis].
  • Example language (illustrative): "This says it works for anxiety, depression and pain all at once. Old patent-medicine adverts made the same kind of promise. What would you want to know before trusting it?"
  • Watch for: Your own sarcasm; the client feeling foolish. Working when: the client can name warning signs in a new advert on their own.

4.9 Working with a client who wants to keep using a product

  • Purpose / when: An adult client values a legal product and does not want to stop.
  • Steps: (1) Acknowledge the choice is theirs. (2) Ask what it does for them and what they would miss. (3) Encourage them to tell their doctor or pharmacist and to keep the label. (4) Agree warning signs that mean they will seek medical help (new confusion, hallucinations, unusual drowsiness, rash). (5) Keep working on the underlying distress [synthesis]. Do not advise on stopping or changing it.
  • Example language (illustrative): "It's your decision. My part is to make sure your doctor knows, and that we keep working on the stress underneath."
  • Watch for: Arguing, which tends to strengthen commitment; signs of escalating use (see 4.10). Working when: the alliance holds and a medical professional is informed.

4.10 Screening for dependence and routing to specialist help

  • Purpose / when: When use of a sedative, "calm" or stimulant product seems to be increasing, hard to control, or causing withdrawal-like distress. The Science Museum notes that historical tonics often contained addictive substances [source: Science Museum]; the FDA warns of dependence-related harms with tianeptine products [uncertain: not verified beyond the harms listed in the warning].
  • Steps: (1) Ask about frequency, control, craving, attempts to cut down and consequences, using a validated screening tool you are trained in. (2) If dependence is possible, refer to the client's doctor or a specialist substance-use service, which will manage any reduction. (3) Continue psychological support alongside [synthesis].
  • Example language (illustrative): "It sounds like it's getting harder to go without it. That's common, and it's something a doctor or a specialist service can help with safely. Can we talk about getting that set up?"
  • Watch for: Abrupt self-withdrawal (route to medical care); shame about "getting hooked on a supplement". Working when: the client is linked to a service that can manage withdrawal.

4.11 Offering supported care for the underlying distress

  • Purpose / when: Once safety is in hand, with clients whose "nerves" are anxiety, low mood, insomnia, stress or fatigue.
  • Steps: (1) Carry out a standard assessment of the presenting problem. (2) Offer, or refer for, the evidence-based psychological treatment that current national guidance recommends for that problem in your country (for example, CBT-based treatments for anxiety disorders and insomnia) [synthesis; guideline specifics uncertain: not verified]. (3) For fatigue, routine medical assessment comes first [synthesis]. (4) Agree goals in the client's own terms.
  • Example language (illustrative): "What the tonic promised was more calm and more energy. Those are good goals. Let's look at approaches that have been tested for exactly that."
  • Watch for: Presenting any treatment as a cure-all, which repeats the tonic's promise; any physical illness being treated as "nerves" (route to a doctor). Working when: the client engages with a tested approach and reports change on agreed measures.

4.12 Online and chatbot health-advice literacy

  • Purpose / when: With clients who look up remedies online or ask chatbots for health or diet advice.
  • Steps: (1) Ask how they choose which advice to follow. (2) Share, in outline, that bromide toxicity has recently been reported in a man who followed chatbot dietary advice and was admitted to hospital with psychosis [source: Packer 2025]. (3) Agree a rule of thumb: check any substance or supplement with a pharmacist or doctor before taking it [synthesis].
  • Example language (illustrative): "Online answers can sound very confident. Before you take anything new, could we agree you'll run it past a pharmacist first?"
  • Watch for: Fear of all medical information; the client hiding use. Working when: the client checks before trying new products.

4.13 Family-history work: ancestors and "nerves"

  • Purpose / when: When a client's family story includes a relative's "nervous breakdown", a remedy habit, an asylum admission or an infant death that may have involved soothing products.
  • Steps: (1) Invite the story and the client's feelings about it. (2) Offer historical context: bromide toxicity was linked to a share of psychiatric admissions in that era (the source gives roughly 1-10% and calls the data hard to document) [source: Packer 2025]; unlabelled soothing syrups with morphine killed many infants before labelling laws [source: FDA Milestones]. (3) Help the client separate what the relative knew at the time from what is known now. (4) Explore any inherited beliefs ("we have weak nerves") and their effects today [synthesis]. (5) If the client wants records, point to archives and family-history services [synthesis].
  • Example language (illustrative): "Your great-grandmother was doing what the adverts and many doctors told people to do. It sounds like it may have harmed her, and you're carrying some of that."
  • Watch for: Speculating about a specific cause of a relative's illness or death; intergenerational guilt. Working when: the client holds a more compassionate, accurate account.

4.14 Repair with a client harmed by a product

  • Purpose / when: A client who was harmed (toxicity, dependence, delayed treatment, money lost) by a nerve, calm or brain product.
  • Steps: (1) Acknowledge the harm plainly. (2) Make sure medical follow-up is in place. (3) Work with shame ("I should have known") by noting how such products are marketed [source: BMA 1909, 1912; FDA tianeptine warning]. (4) Work with anger at sellers or at the health system that failed to help. (5) If the client wants, support them in reporting the product (4.17) or seeking advice on legal routes [synthesis]. (6) Rebuild trust in tested care.
  • Example language (illustrative): "You were looking for relief, and the product was sold as if it would give it. The harm is not a sign of foolishness."
  • Watch for: Self-blame turning into hopelessness (assess risk, 4.20); avoidance of all medical care. Working when: the client re-engages with care and the harm is integrated into their story.

4.15 Safeguarding infants, children and dependent adults

  • Purpose / when: When you learn that an infant, child or dependent adult is being given an unapproved sedative, "soothing", "calm" or imported remedy, or shows signs of toxicity.
  • Steps: (1) Treat it as a safety concern; infantile bromism has been linked to an illegal imported bromide product [source: Packer 2025], and soothing syrups historically killed infants [source: FDA Milestones]. (2) If the child is unwell, arrange urgent medical care. (3) Follow your local child-protection or adult-safeguarding procedure and any mandatory-reporting duty. (4) Talk with the carer without blame: often they are following family or cultural practice [synthesis]. (5) Never name or share details of the child beyond what the safeguarding route requires.
  • Example language (illustrative): "I can see you want to settle her. Some products like this have made babies seriously ill, so I need to make sure a doctor checks her and that we get the right support."
  • Watch for: Cultural assumptions; delay while you "build trust". Working when: the child has been medically assessed and the safeguarding route is followed.

4.16 Older adults and cognitive change

  • Purpose / when: With older clients or their families when memory, confusion or mood change appears and the person uses several remedies or supplements.
  • Steps: (1) Ask carers about everything taken, including old family remedies and online products. (2) Encourage a medication review and a medical check before attributing changes to dementia or depression [synthesis]. Bromism can produce confusion and memory loss and is often missed [source: Packer 2025; Clinical Toxicology case report].
  • Example language (illustrative): "Before we assume this is memory loss, it's worth a doctor checking everything he takes, including anything from the shop."
  • Watch for: Family conflict over "natural" remedies. Working when: a medical review has happened.

4.17 Supporting adverse-event reporting

  • Purpose / when: After a suspected reaction to a product.
  • Steps: (1) Explain that reactions can be reported to the regulator; in the US the FDA asks for reports to MedWatch [source: FDA tianeptine warning]. In the UK the MHRA Yellow Card scheme takes such reports [uncertain: not verified]. (2) Help the client gather the label and dates. (3) The report can be made by the client, a clinician or both [synthesis].
  • Example language (illustrative): "Reporting this helps the regulator spot problems with products. Would you like help putting the details together?"
  • Watch for: Pressure on the client; breach of confidentiality (report clinical details only with consent or under your policy). Working when: a report is filed if the client wants it.

4.18 When a colleague or institution sells or recommends such products

  • Purpose / when: A colleague, clinic or wellness centre sells or promotes nerve tonics, "calm" supplements or unapproved "mood" products to clients.
  • Steps: (1) Note the facts. (2) Raise it with the colleague if safe, referring to professional ethics: selling products to clients can create a conflicting relationship (APA Ethics Code Standard 3.05, Multiple Relationships) [source: APA Ethics Code; application synthesis]. (3) If unresolved or if clients are at risk, use your organisation's governance route and then your licensing or registration body's complaints process [synthesis]. (4) If a product is unapproved or harmful, report it to the regulator (4.17). (5) Never take part in promoting it.
  • Example language (illustrative): "I'm worried that offering these products to our clients mixes a sales relationship with therapy, and some of them carry regulator warnings. Can we talk about stopping it?"
  • Watch for: Your own discomfort in challenging seniors; retaliation (document and seek supervision). Working when: the practice stops or is escalated appropriately.

4.19 Using history in public and team education

  • Purpose / when: Teaching, outreach, museum or heritage work, or community talks.
  • Steps: (1) Use museum objects and the BMA volumes as case studies of claims versus evidence [source: Science Museum; BMA 1909, 1912]. (2) Link to present-day warnings [source: FDA tianeptine warning]. (3) Avoid naming or mocking individual buyers or patients; use role descriptions [synthesis].
  • Example language (illustrative): "This bottle promised to strengthen the nerves; the museum notes it contained strychnine. Today the same kind of promise appears on products sold online."
  • Watch for: Nostalgia or comedy that hides harm. Working when: participants can transfer the lesson to products they see now.

4.20 Suicide-risk assessment where despair, intoxication or dependence are present

  • Purpose / when: When a client harmed by products, struggling with dependence, or in despair after failed "cures" shows hopelessness or suicidal thoughts.
  • Steps: (1) Ask directly about suicidal thoughts, using your service's standard risk-assessment approach. (2) Build a safety plan, including people and services to contact; lethal-means counselling covers safe storage or removal of medicines and products, with no method detail. (3) Share crisis resources: 988 Suicide & Crisis Lifeline (US); Samaritans 116 123 (UK and Ireland). (4) Coordinate with medical care where intoxication may be affecting mood [synthesis].
  • Example language (illustrative): "When things have felt this hopeless, some people think about ending their life. Has that been on your mind?"
  • Watch for: Intoxication or withdrawal altering risk quickly; safe-messaging (no method details, no glamorising). Working when: a safety plan is in place and the client knows how to reach help.

5. Handling problems

The guidance in this section is [synthesis] unless a source is named.

  • The client is convinced the product works. Do not argue efficacy. Explore what improved, when and what else changed; keep the medical professional informed; work on the distress directly (4.9, 4.11) [synthesis].
  • The client feels judged or ashamed. Name that many people use such products and that they are marketed persuasively; the BMA documented testimonials, guarantees and attacks on doctors as sales tactics [source: BMA 1909, 1912]. Return to curiosity (4.6) [synthesis].
  • The client asks you whether to stop, reduce or combine a product or medicine. Decline to advise, explain why, and route to the prescriber or pharmacist the same day if there is any risk (4.5). Never suggest abrupt stopping [synthesis].
  • Symptoms look psychiatric but the history includes remedies. Keep a medical or toxic cause on the list; bromism is easy to miss and can mimic psychosis [source: Packer 2025; Clinical Toxicology case report]. Route to medical review before changing the formulation (4.3) [synthesis].
  • Overwhelm on learning of a relative's harm. Slow down, ground the session, and pace historical material; offer the choice to stop the topic at any time (4.13) [synthesis].
  • Non-adherence to medical referral. Explore barriers (cost, distrust of doctors, past dismissal); offer practical help to book; for urgent signs, follow your emergency policy [synthesis].
  • Rupture after you raise safety concerns. Acknowledge the client's experience of being lectured; repair explicitly; restate that the choice about legal products is theirs while safety routing is yours (4.9) [synthesis].
  • Cultural or family remedy traditions. Approach with cultural humility, using the Cultural Formulation Interview; separate respect for a tradition from concern about a specific unregulated product; for children, safeguarding still applies (4.6, 4.15) [synthesis].
  • Religious or spiritual framing of "nerves". Where the difficulty centres on a tradition or faith, the DSM-5-TR "Religious or Spiritual Problem" (Z65.8) may be named [source: ICD-10-CM Z65.8 (Unbound Medicine)]; DSM-5-TR wording [uncertain: not verified].
  • Dependence with denial. Use motivational, non-confrontational conversation; link to a specialist service when the client is ready; keep risk under review (4.10, 4.20) [synthesis].
  • The client uses "nootropic" or "research chemical" products for focus or mood. Share, factually, the FDA's warning on unapproved tianeptine products sold this way [source: FDA tianeptine warning]; route to medical care; screen for dependence [synthesis].
  • A colleague dismisses your concern as "only a supplement". Point to regulator warnings; document; use governance routes (4.18) [synthesis].
  • Fatigue or physical symptoms are being treated as "nerves". Neurasthenia was a catch-all diagnosis [source: Science Museum]; make sure physical causes are assessed by a doctor and do not frame any product or therapy as treating a physical disease [synthesis].
  • Eating, weight or diet changes appear alongside product use. Screen for disordered eating; refer to a registered dietitian or an eating-disorder service; the National Alliance for Eating Disorders offers support [synthesis].
  • Allegations against a seller without official findings. Report them as allegations only; leave formal findings to regulators and courts [synthesis].

Harm account

What was actually done

From about 1870 to 1960, manufacturers in Britain, Europe and North America sold branded "nerve" tonics, pills, powders and "neurasthenic serums" direct to the public with claims to strengthen or calm the nerves and to treat neurasthenia, depression, sleeplessness and many physical complaints [source: Science Museum; Science Museum Group collection; BMA 1909, 1912]. The Science Museum records that many contained strychnine, morphine, lithium salts or cocaine, and that examples in its collection include a tonic containing strychnine sold 1892-1943 for depression and neurasthenia and probably taken by veterans with "shell-shock" [source: Science Museum; Science Museum Group collection]. Bromide compounds were widely sold as sedatives and "nerve" remedies in the early 20th century [source: Packer 2025]. The BMA's analyses found cheap ingredients sold at many times their cost and some products mislabelled as free of opium while containing morphine [source: BMA 1909]. In the US, the FDA records that an unlabelled soothing syrup laced with morphine "killed many infants" and that the 1937 Elixir Sulfanilamide killed 107 people, prompting the 1938 Act [source: FDA Milestones]. Commercial animal-extract injections followed Brown-Séquard's 1889 rejuvenation claims [source: History Today; Science Museum].

How it caused harm

  • Toxicity and psychiatric illness. Bromism causes hallucinations, paranoia, confusion and aggression and was linked to roughly 1-10% of psychiatric admissions in its era (data hard to document) [source: Packer 2025]; a published case describes psychiatric admission with confusion, hallucinations and memory loss from a non-prescription bromide product [source: Clinical Toxicology case report].
  • Dependence. Hidden addictive ingredients (morphine, cocaine) made dependence likely [source: Science Museum].
  • Deaths of infants and others. Unlabelled sedative syrups killed infants; an untested elixir killed 107 people [source: FDA Milestones].
  • Delayed or replaced care and financial exploitation. The BMA documented cure-all claims for serious conditions and products costing a fraction of their price, urging people to seek proper medical advice [source: BMA 1909, 1912].
  • Present-day harm. Unapproved tianeptine products marketed for anxiety and depression are linked to seizures, loss of consciousness and death [source: FDA tianeptine warning]; bromism still arises from online products, imported remedies and a recent case of chatbot dietary advice [source: Packer 2025].

Recognising it today

  • Products marketed for "nerves", stress, calm, mood or focus as "nootropics", "research chemicals" or supplements, especially from gas stations, vape shops and online sellers [source: FDA tianeptine warning].
  • Cure-all claims, testimonials, guarantees and attacks on medicine [source: BMA 1909, 1912].
  • Unexplained confusion, hallucinations, paranoia or an acne-like rash in someone using remedies; laboratory oddities that clinicians may first dismiss as error [source: Packer 2025].
  • Imported or unlabelled "soothing" products given to infants [source: Packer 2025; FDA Milestones].
  • Vintage tonics treated as charming heritage objects without their harms [synthesis].

What to do instead and how to help those harmed

  • Route suspected toxicity to urgent medical care and poison control (US Poison Help 1-800-222-1222; 911 if unconscious or not breathing) [source: FDA tianeptine warning]; report adverse events to the regulator (FDA MedWatch) [source: FDA tianeptine warning].
  • Offer or refer for evidence-based care of anxiety, low mood, insomnia and fatigue after medical assessment (4.11) [synthesis].
  • Dependence: link to the client's doctor or a specialist substance-use service (4.10) [synthesis].
  • Children: urgent medical care and child-protection procedures, including mandatory reporting where it applies (4.15) [synthesis].
  • Survivors and families: repair work, family-history work and support for reporting or legal advice (4.13, 4.14) [synthesis].
  • Crisis support: 988 (US); Samaritans 116 123 (UK and Ireland).

Sources

← Previous · XVI-039Vibratory massagers and vibrotherapy for hysteriaNext · XVI-041 →Asylum hydrotherapy